Loading...
Market
Number of Hyrimoz Competitors in the Biosimilar Market by End of 2024
5
Resolution / Starting Odds
0-2 competitors • 25%
3-5 competitors • 25%
6-8 competitors • 25%
More than 8 competitors • 25%
Pharmaceutical industry reports and CVS Health announcements
Story
CVS Health Replaces Humira with Hyrimoz on April 1, Biosimilar Market Share Surges to 36%
Apr 16, 2024, 02:25 PM
Following a strategic decision by CVS Health, credited by analysts including Elizabeth Anderson from Evercore ISI, there has been a significant increase in the prescription rates of biosimilar versions of Humira, specifically Hyrimoz. CVS Health removed Humira from its major commercial formularies on April 1st and replaced it with Hyrimoz, a biosimilar jointly marketed by its subsidiary Cordavis. This change led to a surge in new prescriptions for Hyrimoz, with the market share of biosimilar versions of Humira jumping from 5% to 36% in just the first week of April.
View original story
Similar markets
Less than 20% • 20%
20% to 35% • 20%
36% to 50% • 20%
51% to 65% • 20%
More than 65% • 20%
Remains 9 • 25%
10 to 12 • 25%
13 to 15 • 25%
More than 15 • 25%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
No competitors • 33%
1-2 competitors • 33%
3 or more competitors • 33%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%
Equal market share between Biocon and Biogen • 34%
No competitors • 25%
1 competitor • 25%
2 competitors • 25%
3 or more competitors • 25%
No competitors respond • 25%
1-2 competitors respond • 25%
3-5 competitors respond • 25%
More than 5 competitors respond • 25%
No competitive drugs launched • 25%
1-2 competitive drugs launched • 25%
3-5 competitive drugs launched • 25%
More than 5 competitive drugs launched • 25%
Under 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%